Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
52
NRC Quote, Financials, Valuation and Earnings
Last price:
$18.82
Seasonality move
:
-5.71%
Day range:
$18.68 - $19.16
52-week range:
$9.76 - $19.39
Dividend yield:
2.55%
P/E ratio:
26.69x
P/S ratio:
3.08x
P/B ratio:
29.77x
Volume:
29.7K
Avg. volume:
93.5K
1-year change:
5.91%
Market cap:
$426.2M
Revenue:
$143.1M
EPS (TTM):
$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NRC
National Research Corp.
|
-- | -- | -- | -- | -- |
|
CERT
Certara, Inc.
|
$104.6M | $0.11 | 3.04% | 150.07% | $12.54 |
|
DRIO
DarioHealth Corp.
|
$5.7M | -$2.42 | -32.08% | -68.96% | $18.25 |
|
FORA
Forian, Inc.
|
$7.3M | $0.01 | 32.51% | 56.25% | $2.10 |
|
GDRX
GoodRx Holdings, Inc.
|
$194.5M | $0.09 | -2.9% | 420.34% | $4.88 |
|
SPOK
Spok Holdings, Inc.
|
$35.9M | $0.24 | 2.09% | 18.18% | $20.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NRC
National Research Corp.
|
$18.81 | -- | $426.2M | 26.69x | $0.12 | 2.55% | 3.08x |
|
CERT
Certara, Inc.
|
$8.91 | $12.54 | $1.4B | 131.93x | $0.00 | 0% | 3.45x |
|
DRIO
DarioHealth Corp.
|
$10.04 | $18.25 | $24.1M | -- | $0.00 | 0% | 5.57x |
|
FORA
Forian, Inc.
|
$2.11 | $2.10 | $65.6M | 49.00x | $0.00 | 0% | 2.34x |
|
GDRX
GoodRx Holdings, Inc.
|
$2.77 | $4.88 | $940.2M | 32.25x | $0.00 | 0% | 1.27x |
|
SPOK
Spok Holdings, Inc.
|
$13.03 | $20.00 | $268.4M | 16.28x | $0.31 | 9.59% | 1.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NRC
National Research Corp.
|
84.83% | 2.343 | 28.57% | 0.39x |
|
CERT
Certara, Inc.
|
22.36% | 0.910 | 15.74% | 1.94x |
|
DRIO
DarioHealth Corp.
|
29.69% | 1.040 | 75.99% | 3.72x |
|
FORA
Forian, Inc.
|
0.06% | 0.709 | 0.03% | 3.58x |
|
GDRX
GoodRx Holdings, Inc.
|
47.58% | 0.637 | 37.77% | 2.62x |
|
SPOK
Spok Holdings, Inc.
|
4.71% | 0.927 | 2.07% | 0.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NRC
National Research Corp.
|
$20M | $7.7M | 17.01% | 61.55% | 22.36% | $10.2M |
|
CERT
Certara, Inc.
|
$50.9M | $6.8M | 0.79% | 1.02% | 6.53% | $25.5M |
|
DRIO
DarioHealth Corp.
|
$3M | -$9.5M | -28.66% | -41.55% | -189.42% | -$7.4M |
|
FORA
Forian, Inc.
|
$4M | -$299.3K | -2.24% | -2.86% | -3.86% | -$439.7K |
|
GDRX
GoodRx Holdings, Inc.
|
$161.2M | $26.4M | 2.63% | 4.78% | 13.48% | $58M |
|
SPOK
Spok Holdings, Inc.
|
$20M | $4.5M | 10.33% | 10.88% | 13.38% | $7.6M |
National Research Corp. vs. Competitors
-
Which has Higher Returns NRC or CERT?
Certara, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of 1.46%. National Research Corp.'s return on equity of 61.55% beat Certara, Inc.'s return on equity of 1.02%.
Company Gross Margin Earnings Per Share Invested Capital NRCNational Research Corp.57.82% $0.18 $94.4M CERTCertara, Inc.48.67% $0.01 $1.4B -
What do Analysts Say About NRC or CERT?
National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Certara, Inc. has an analysts' consensus of $12.54 which suggests that it could grow by 39.82%. Given that Certara, Inc. has higher upside potential than National Research Corp., analysts believe Certara, Inc. is more attractive than National Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings NRCNational Research Corp.0 0 0 CERTCertara, Inc.6 7 0 -
Is NRC or CERT More Risky?
National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison Certara, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NRC or CERT?
National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.55%. Certara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. Certara, Inc. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NRC or CERT?
National Research Corp. quarterly revenues are $34.6M, which are smaller than Certara, Inc. quarterly revenues of $104.6M. National Research Corp.'s net income of $4M is higher than Certara, Inc.'s net income of $1.5M. Notably, National Research Corp.'s price-to-earnings ratio is 26.69x while Certara, Inc.'s PE ratio is 131.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 3.08x versus 3.45x for Certara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRCNational Research Corp.3.08x 26.69x $34.6M $4M CERTCertara, Inc.3.45x 131.93x $104.6M $1.5M
-
Which has Higher Returns NRC or DRIO?
DarioHealth Corp. has a net margin of 11.54% compared to National Research Corp.'s net margin of -41.48%. National Research Corp.'s return on equity of 61.55% beat DarioHealth Corp.'s return on equity of -41.55%.
Company Gross Margin Earnings Per Share Invested Capital NRCNational Research Corp.57.82% $0.18 $94.4M DRIODarioHealth Corp.60.22% -$3.05 $106.6M -
What do Analysts Say About NRC or DRIO?
National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand DarioHealth Corp. has an analysts' consensus of $18.25 which suggests that it could grow by 81.77%. Given that DarioHealth Corp. has higher upside potential than National Research Corp., analysts believe DarioHealth Corp. is more attractive than National Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings NRCNational Research Corp.0 0 0 DRIODarioHealth Corp.3 1 0 -
Is NRC or DRIO More Risky?
National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison DarioHealth Corp. has a beta of 1.077, suggesting its more volatile than the S&P 500 by 7.716%.
-
Which is a Better Dividend Stock NRC or DRIO?
National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.55%. DarioHealth Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. DarioHealth Corp. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NRC or DRIO?
National Research Corp. quarterly revenues are $34.6M, which are larger than DarioHealth Corp. quarterly revenues of $5M. National Research Corp.'s net income of $4M is higher than DarioHealth Corp.'s net income of -$2.1M. Notably, National Research Corp.'s price-to-earnings ratio is 26.69x while DarioHealth Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 3.08x versus 5.57x for DarioHealth Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRCNational Research Corp.3.08x 26.69x $34.6M $4M DRIODarioHealth Corp.5.57x -- $5M -$2.1M
-
Which has Higher Returns NRC or FORA?
Forian, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of -1.95%. National Research Corp.'s return on equity of 61.55% beat Forian, Inc.'s return on equity of -2.86%.
Company Gross Margin Earnings Per Share Invested Capital NRCNational Research Corp.57.82% $0.18 $94.4M FORAForian, Inc.50.97% -$0.00 $31.1M -
What do Analysts Say About NRC or FORA?
National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Forian, Inc. has an analysts' consensus of $2.10 which suggests that it could fall by -0.47%. Given that Forian, Inc. has higher upside potential than National Research Corp., analysts believe Forian, Inc. is more attractive than National Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings NRCNational Research Corp.0 0 0 FORAForian, Inc.0 1 0 -
Is NRC or FORA More Risky?
National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison Forian, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NRC or FORA?
National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.55%. Forian, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. Forian, Inc. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NRC or FORA?
National Research Corp. quarterly revenues are $34.6M, which are larger than Forian, Inc. quarterly revenues of $7.8M. National Research Corp.'s net income of $4M is higher than Forian, Inc.'s net income of -$151.2K. Notably, National Research Corp.'s price-to-earnings ratio is 26.69x while Forian, Inc.'s PE ratio is 49.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 3.08x versus 2.34x for Forian, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRCNational Research Corp.3.08x 26.69x $34.6M $4M FORAForian, Inc.2.34x 49.00x $7.8M -$151.2K
-
Which has Higher Returns NRC or GDRX?
GoodRx Holdings, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of 0.57%. National Research Corp.'s return on equity of 61.55% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.
Company Gross Margin Earnings Per Share Invested Capital NRCNational Research Corp.57.82% $0.18 $94.4M GDRXGoodRx Holdings, Inc.82.22% $0.00 $1.1B -
What do Analysts Say About NRC or GDRX?
National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $4.88 which suggests that it could grow by 76.29%. Given that GoodRx Holdings, Inc. has higher upside potential than National Research Corp., analysts believe GoodRx Holdings, Inc. is more attractive than National Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings NRCNational Research Corp.0 0 0 GDRXGoodRx Holdings, Inc.6 5 0 -
Is NRC or GDRX More Risky?
National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.
-
Which is a Better Dividend Stock NRC or GDRX?
National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.55%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research Corp. pays 45.99% of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NRC or GDRX?
National Research Corp. quarterly revenues are $34.6M, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. National Research Corp.'s net income of $4M is higher than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, National Research Corp.'s price-to-earnings ratio is 26.69x while GoodRx Holdings, Inc.'s PE ratio is 32.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 3.08x versus 1.27x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRCNational Research Corp.3.08x 26.69x $34.6M $4M GDRXGoodRx Holdings, Inc.1.27x 32.25x $196M $1.1M
-
Which has Higher Returns NRC or SPOK?
Spok Holdings, Inc. has a net margin of 11.54% compared to National Research Corp.'s net margin of 9.46%. National Research Corp.'s return on equity of 61.55% beat Spok Holdings, Inc.'s return on equity of 10.88%.
Company Gross Margin Earnings Per Share Invested Capital NRCNational Research Corp.57.82% $0.18 $94.4M SPOKSpok Holdings, Inc.58.95% $0.15 $156.1M -
What do Analysts Say About NRC or SPOK?
National Research Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.17%. Given that Spok Holdings, Inc. has higher upside potential than National Research Corp., analysts believe Spok Holdings, Inc. is more attractive than National Research Corp..
Company Buy Ratings Hold Ratings Sell Ratings NRCNational Research Corp.0 0 0 SPOKSpok Holdings, Inc.1 0 0 -
Is NRC or SPOK More Risky?
National Research Corp. has a beta of 0.447, which suggesting that the stock is 55.256% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.
-
Which is a Better Dividend Stock NRC or SPOK?
National Research Corp. has a quarterly dividend of $0.12 per share corresponding to a yield of 2.55%. Spok Holdings, Inc. offers a yield of 9.59% to investors and pays a quarterly dividend of $0.31 per share. National Research Corp. pays 45.99% of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Spok Holdings, Inc.'s is not.
-
Which has Better Financial Ratios NRC or SPOK?
National Research Corp. quarterly revenues are $34.6M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. National Research Corp.'s net income of $4M is higher than Spok Holdings, Inc.'s net income of $3.2M. Notably, National Research Corp.'s price-to-earnings ratio is 26.69x while Spok Holdings, Inc.'s PE ratio is 16.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research Corp. is 3.08x versus 1.94x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NRCNational Research Corp.3.08x 26.69x $34.6M $4M SPOKSpok Holdings, Inc.1.94x 16.28x $33.9M $3.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
